trending Market Intelligence /marketintelligence/en/news-insights/trending/p7mte1LfCXZvGvCO8L1IMQ2 content esgSubNav
In This List

Bausch Health ends constipation drug partnership with Cipher Pharmaceuticals

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Bausch Health ends constipation drug partnership with Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. said Bausch Health Cos Inc. is terminating their partnership for constipation drug Trulance, citing breach of the agreement's certain provisions.

Oakville, Ontario-based Cipher acquired the exclusive Canadian marketing and selling rights to Trulance from Synergy Pharmaceuticals Inc. in February 2018. Bausch Health then bought certain assets of Synergy Pharmaceuticals in March 2019, including Trulance.

Trulance is approved by the U.S. Food and Drug Administration to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation.

As part of a strategic review process for its Canadian commercial assets, Cipher was negotiating the sublicensing of Trulance with multiple parties.

Cipher said the termination is without merit and plans on challenging it.